Literature DB >> 21777363

Influence of obesity on tumour volume in patients with prostate cancer.

Umberto Capitanio1, Nazareno Suardi, Alberto Briganti, Andrea Gallina, Firas Abdollah, Giovanni Lughezzani, Andrea Salonia, Massimo Freschi, Francesco Montorsi.   

Abstract

OBJECTIVE: • To investigate the association between body mass index and tumour volume at radical prostatectomy in a large European population. PATIENTS AND METHODS: • Recent data support the hypothesis that the hormonal environment in overweight and obese men may alter androgen-dependent prostate growth. Body mass index (BMI) has been implicated in prostate cancer pathophysiology. • We analysed 1275 patients with prostate cancer who underwent radical prostatectomy at a single tertiary care institution. Mean tumour volume (TV) was evaluated according to BMI WHO categories (normal <25 kg/m(2) vs overweight 25-30 kg/m(2) vs obese 30-35 kg/m(2) vs severely obese >35 kg/m(2)). • Univariable linear regression analyses targeted the association between BMI and TV at radical prostatectomy. Multivariable analyses were adjusted for age, prostate-specific antigen value, biopsy Gleason sum, clinical stage and prostate volume.
RESULTS: • Mean BMI was 26.3 kg/m(2) (median 26; range 16.7-42.0). Mean TV was 5.6 mL (median 3.3; range 0.1-61.2). The mean prostate-specific antigen value was 10.3 ng/dL (median 6.6; range 0.3-327). • The mean TV was 5.0, 5.8, 6.3 and 9.2 mL in normal, overweight, obese and severely obese patients, respectively (P= 0.03). TVs in men with a normal BMI were 84% smaller than in severely obese men (5.0 vs 9.2 mL). • On univariable analysis, BMI was correlated with TV at radical prostatectomy (P < 0.001). On multivariable analysis, BMI reached the independent predictor status after adjustment for age, prostate-specific antigen value, biopsy Gleason score, clinical stage and prostate volume (P= 0.03).
CONCLUSION: • We showed that BMI is independently associated with prostate cancer volume at radical prostatectomy. The present results confirm that obesity may play a key role in prostate cancer pathophysiology.
© 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2011        PMID: 21777363     DOI: 10.1111/j.1464-410X.2011.10453.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  6 in total

Review 1.  Clinical management of obese patients with cancer.

Authors:  Wenjing Tao; Jesper Lagergren
Journal:  Nat Rev Clin Oncol       Date:  2013-07-16       Impact factor: 66.675

2.  [Clinical and histopathological parameters of prostate cancer: influence of anthropometric indices].

Authors:  B Löppenberg; F Roghmann; M Brock; C von Bodmann; C J Michels; J Noldus; J Palisaar
Journal:  Urologe A       Date:  2015-01       Impact factor: 0.639

3.  Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro.

Authors:  Ricardo Ribeiro; Cátia Monteiro; Virgínia Cunha; Maria José Oliveira; Mariana Freitas; Avelino Fraga; Paulo Príncipe; Carlos Lobato; Francisco Lobo; António Morais; Vítor Silva; José Sanches-Magalhães; Jorge Oliveira; Francisco Pina; Anabela Mota-Pinto; Carlos Lopes; Rui Medeiros
Journal:  J Exp Clin Cancer Res       Date:  2012-04-02

4.  Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2.

Authors:  K M Biernacka; R A Persad; A Bahl; D Gillatt; J M P Holly; C M Perks
Journal:  Endocr Relat Cancer       Date:  2016-10-17       Impact factor: 5.678

5.  Growth and Progression of TRAMP Prostate Tumors in Relationship to Diet and Obesity.

Authors:  Melissa J L Bonorden; Michael E Grossmann; Sarah A Ewing; Olga P Rogozina; Amitabha Ray; Katai J Nkhata; D Joshua Liao; Joseph P Grande; Margot P Cleary
Journal:  Prostate Cancer       Date:  2012-12-04

6.  The relationship between obesity and prostate cancer: from genetics to disease treatment and prevention.

Authors:  Giovanni Lughezzani
Journal:  BMC Med       Date:  2012-09-25       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.